Thymosin Alpha-1
Thymalfasin, an N-acetylated 28-amino-acid thymic peptide
Thymic peptide research focused on immune modulation, T-cell function, and host-defense signaling.
Route
Subcutaneous.
Common format
10 mg vial
Research focus
viral infection adjunct research
Evidence level
Limited Human Evidence
Typical cycle
8–12 weeks
ImmuneThymosin Alpha-1 in 30 seconds
Atlas Fast ReadWhat it is
Thymalfasin, an N-acetylated 28-amino-acid thymic peptide
Why people care
Thymic peptide research focused on immune modulation, T-cell function, and host-defense signaling.
Human evidence
Limited Human Evidence — Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.
Biggest misconception
Key gaps include larger independent trials, clearer dose-response data, long-term safety, clinically meaningful endpoints, and evidence that findings generalize beyond the narrow populations or routes already studied.
Bottom line
Thymosin Alpha-1 has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims.
Overview
What is Thymosin Alpha-1?
Thymosin Alpha-1 is thymalfasin, an N-acetylated 28-amino-acid thymic peptide. Thymic peptide research focused on immune modulation, T-cell function, and host-defense signaling.
Thymosin alpha-1 was isolated from thymic peptide preparations in the 1970s and later developed as thymalfasin. It is approved in some countries and has been studied in viral disease, immune dysfunction, and critical illness.
Mechanism
How it works
Modulates innate and adaptive immunity, including dendritic-cell signaling, T-cell maturation/function, toll-like receptor pathways, and cytokine responses. It behaves more as an immune modulator than a simple immune stimulant.
Research areas
Evidence
What does the evidence actually say?
Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.
Preclinical Evidence
Limited Human Evidence
Strong Human Evidence
Human evidence
Preclinical evidence
Knowledge gaps
Protocol
Research protocol
Dose
Frequency
Timing
Route
Cycle length
Reconstitution
Storage
Monitoring
Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.
Safety
Safety, side effects, and precautions
Side effects
Contraindications
Interactions
Stacks
Common stacks
Thymosin Alpha-1 + standard-of-care therapy
In research and some international clinical settings, thymalfasin is studied as an adjunct rather than a replacement for standard therapy.
Evidence is disease-specific; combinations must be clinician/protocol directed.
Questions
FAQ
References
Sources
Atlas
The Atlas verdict
Thymosin Alpha-1 has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims. The most defensible use of the literature is to separate what has actually been measured in people from what is still extrapolated from mechanism or animal work.